In one study [37], immune-deficient transgenic mice (NSG-S) injected with human CD34+ cells experienced greater reduction in tumor burden compared to their immune-incompetent counterparts, suggesting that normal hematopoiesis may provide some clinical benefit with CAR T response in vivo. The gene discussed is CD34; the disease is neoplasm.